A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth

Angiogenesis

Volumn 5, Issue 3, 2002, Pages 203-214

  Arakelyan, L ^a   Vainstein, V ^a   Agur, Z ^a,b  

^a Institute for Medical Biomathematics Isarel   (Israel)

^b Optimata Ltd   (Israel)

Author keywords

Angiopoietin; Destabilization; Model; Vascular endothelial growth factor; Vessel regression

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN;

ALGORITHM; ANGIOGENESIS; ARTICLE; CELL DENSITY; CELL PROLIFERATION; COMPUTER MODEL; COMPUTER SIMULATION; HUMAN; HUMAN CELL; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; TUMOR GROWTH;

ALGORITHMS; ANGIOGENESIS INHIBITORS; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037840352     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023841921971     Document Type: Article

References (49)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1(1): 27-31.
2. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
3. O'Reilly MS et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
4. O'Reilly MS et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
6. Yangopoulos GD, Davis S, Gale NW et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
7. Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000; 21: 505-15.
8. Danielsen T, Rofstad EK. The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts. Br J Cancer 2000; 82(9): 1528-34.
9. Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. AJP-Cell Physiol 2001; 280(6): C1367-74.
10. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995; 270(34): 19761-6.
11. Lin P et al. Anti-angiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie-2. Proc Natl Acad Sci 1998; 95: 8829-34.
12. Diaz Flores L et al. Microvascular pericytes: A review of their morphological and functional characteristics. Histol Histopathol 1991; 6: 269-86.
13. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992; 114: 521-32.
14. Shweiki D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
15. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-8.
16. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32.
17. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-42.
18. Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-9.
19. Barleon B, Sozzani S, Zhou D et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336-43.
20. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB 1999; 13: 9-22.
21. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci 1997; 94: 8761-6.
22. Jain RK, Safabakhsh N, Sckell A et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci 1998; 95(18): 10820-25.
23. Holash SJ, Wiegandand GD, Yancopoulos GD. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18: 5356-62.
24. Gilead A, Neeman M. Dynamic remodeling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice. Neoplasia 1999; 1: 226-30.
25. Benjamin LE et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103(2): 159-65.
26. Benjamin LE et al. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125(9): 1591-8.
27. Currie MJ et al. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling. Clin Cancer Res 2001; 7: 918-27.
28. Koga K et al. Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 2001; 61: 6248-54.
29. Davis S, Aldrich TH, Jones PF et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-9.
30. Suri C, Jones PE, Patan S et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-80.
31. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in in vivo angiogenesis. Science 1997; 277: 55-60.
32. Audero E et al. Expression of Angiopoietin-1 in human glioblastoma regulates tumor-induced angiogenesis. Arterioscl Thromb Vasc Biol 2001; 21: 536-41.
33. Stratmann A. Cell type-specific expression of Angiopoietin-1 and Angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998; 153: 1459-66.
34. Kakolyris S et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component. Br J Cancer LH39 2000; 82: 844-51.
35. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7: 987-9.
36. Hahnfeldt P et al. Tumor development under angiogenic signaling: A dynamic theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999; 59: 4770-5.
37. Bellomo N, Preziosi L. Modelling and mathematical problems related to tumor evolution and its interaction with the immune system. Math Comp Modell 2000; 32: 413-52.
38. De Angelis E, Preziosi L. Advection-diffusion models for solid tumour evolution in vivo and related free boundary problem. Math Models Meth Appl 2000; 10: 379-408.
39. Folkman J, D'Amore PA. Blood vessel formation: What is its molecular basis? Cell 1996; 87: 1153-5.
40. Darland DC, D'Amore PA. Blood vessel maturation: Vascular development comes of age. J Clin Invest 1999; 103(2): 157-8.
41. Ahmad SA et al. Differential expression of Angiopoietin-1 and Angiopoietin-2 in colon carcinoma. Cancer 2001; 92: 1138-43.
42. Arakelyan L et al. Multi-scale analysis of angiogenic dynamics and therapy. In Luigi Preziosi (ed): Cancer Modelling and Simulation, UK: CRC Press (in press).
43. Segel LA. Developmental pattern formation and stability theory. In Modeling Dynamic Phenomena in Molecular and Cellular Biology, Chapter 7. Cambridge: Cambridge University Press, 1984.
44. Norton LA. Gompertzian model of human breast cancer growth. Cancer Res 1988; 48: 7067-71.
45. Folkman J. Cancer: Looking outside the genome. Nat Rev Mol Cell Biol 2000; 1: 76-9.
46. Holash J et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284(5422): 1994-8.
47. Folberg R et al. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000 156(2): 361-81.
48. Murayama T. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp Hematol 2002; 30(8): 967-72.
49. Garber K. Angiogenesis inhibitors suffer new setback. Nat Biotechnol 2002; 20: 1067-8.